Diverse Biotech Inc, a United States-based biopharmaceutical company, has named Stella Vnook as its new chief executive officer, it was reported yesterday.
Vnook has more than 25 years' experience. She has most recently held senior leadership roles at Assertio Pharma, Jazz Pharmaceuticals, Catalent and Merck. She started her career in Research and Development in the Emergency Department at Temple University Hospital and later continued that work with oncology specialty interest at Temple/Fox Chase Cancer Centre as a pharmacist. Throughout her career she has developed extensive knowledge in many different therapy categories with a particular emphasis on Oncology, Pain Management and Cardiovascular Diseases.
William Fisher, Diverse Biotech's board chairman, said, 'Diverse Biotech is very excited to bring Stella on board as an experienced, knowledgeable, and innovative Senior Leader. Stella will work hand in hand with the current Diverse Biotech Board to continue to build a world class, innovative, experienced Executive Team.'
Merck reports positive Phase 3 data for investigational two-drug HIV regimen doravirine/islatravir
Novocure announces presentation of new TTFields research at EANO and ESMO 2025 meetings
Minovia Therapeutics' MNV-201 receives FDA Orphan Drug Designation for Myelodysplastic Syndrome
Mabwell to present latest 7MW3711 clinical results at 2025 ESMO Congress
Privo Technologies reports progress in oral cancer trial
Astellas to present VEOZAH (fezolinetant) data at Menopause Society 2025 Annual Meeting
Imaging Biometrics acquires Kirkstall to expand presence in advanced cell culture technologies
Actinium Pharmaceuticals to reveal ATNM-400 data in NSCLC at AACR-NCI-EORTC International Conference